Quiescent human glioblastoma cancer stem cells drive tumor initiation, expansion, and recurrence following chemotherapy

2022 ◽  
Vol 57 (1) ◽  
pp. 32-46.e8
Author(s):  
Xuanhua P. Xie ◽  
Dan R. Laks ◽  
Daochun Sun ◽  
Mungunsarnai Ganbold ◽  
Zilai Wang ◽  
...  
2009 ◽  
Vol 69 (8) ◽  
pp. 3472-3481 ◽  
Author(s):  
Hiroaki Wakimoto ◽  
Santosh Kesari ◽  
Christopher J. Farrell ◽  
William T. Curry ◽  
Cecile Zaupa ◽  
...  

2015 ◽  
Vol 29 (1) ◽  
pp. 105-109 ◽  
Author(s):  
Francesco Alessandrini ◽  
Ilaria Cristofaro ◽  
Maria Di Bari ◽  
Jacopo Zasso ◽  
Luciano Conti ◽  
...  

Tumor Biology ◽  
2012 ◽  
Vol 33 (6) ◽  
pp. 1997-2005 ◽  
Author(s):  
Denise Grant Lanza ◽  
Jun Ma ◽  
Ian Guest ◽  
Chang Uk-Lim ◽  
Anna Glinskii ◽  
...  

2020 ◽  
Vol 295 (52) ◽  
pp. 18328-18342
Author(s):  
Shuhei Suzuki ◽  
Masashi Okada ◽  
Tomomi Sanomachi ◽  
Keita Togashi ◽  
Shizuka Seino ◽  
...  

Postoperative recurrence from microscopic residual disease must be prevented to cure intractable cancers, including pancreatic cancer. Key to this goal is the elimination of cancer stem cells (CSCs) endowed with tumor-initiating capacity and drug resistance. However, current therapeutic strategies capable of accomplishing this are insufficient. Using in vitro models of CSCs and in vivo models of tumor initiation in which CSCs give rise to xenograft tumors, we show that dexamethasone induces expression of MKP-1, a MAPK phosphatase, via glucocorticoid receptor activation, thereby inactivating JNK, which is required for self-renewal and tumor initiation by pancreatic CSCs as well as for their expression of survivin, an anti-apoptotic protein implicated in multidrug resistance. We also demonstrate that systemic administration of clinically relevant doses of dexamethasone together with gemcitabine prevents tumor formation by CSCs in a pancreatic cancer xenograft model. Our study thus provides preclinical evidence for the efficacy of dexamethasone as an adjuvant therapy to prevent postoperative recurrence in patients with pancreatic cancer.


2008 ◽  
Vol 265 (1) ◽  
pp. 124-134 ◽  
Author(s):  
Shi-cang Yu ◽  
Yi-fang Ping ◽  
Liang Yi ◽  
Zhi-hua Zhou ◽  
Jian-hong Chen ◽  
...  

2015 ◽  
Author(s):  
Soo Jung Ha ◽  
Marisol Herrera-Perez ◽  
Jiri Adamec ◽  
R. Timothy Bentley ◽  
Jenna L. Rickus ◽  
...  

2015 ◽  
Vol 212 (12) ◽  
pp. 2057-2075 ◽  
Author(s):  
Aurélie Ladang ◽  
Francesca Rapino ◽  
Lukas C. Heukamp ◽  
Lars Tharun ◽  
Kateryna Shostak ◽  
...  

Tumor initiation in the intestine can rapidly occur from Lgr5+ crypt columnar stem cells. Dclk1 is a marker of differentiated Tuft cells and, when coexpressed with Lgr5, also marks intestinal cancer stem cells. Here, we show that Elp3, the catalytic subunit of the Elongator complex, is required for Wnt-driven intestinal tumor initiation and radiation-induced regeneration by maintaining a subpool of Lgr5+/Dclk1+/Sox9+ cells. Elp3 deficiency dramatically delayed tumor appearance in Apc-mutated intestinal epithelia and greatly prolonged mice survival without affecting the normal epithelium. Specific ablation of Elp3 in Lgr5+ cells resulted in marked reduction of polyp formation upon Apc inactivation, in part due to a decreased number of Lgr5+/Dclk1+/Sox9+ cells. Mechanistically, Elp3 is induced by Wnt signaling and promotes Sox9 translation, which is needed to maintain the subpool of Lgr5+/Dclk1+ cancer stem cells. Consequently, Elp3 or Sox9 depletion led to similar defects in Dclk1+ cancer stem cells in ex vivo organoids. Finally, Elp3 deficiency strongly impaired radiation-induced intestinal regeneration, in part because of decreased Sox9 protein levels. Together, our data demonstrate the crucial role of Elp3 in maintaining a subpopulation of Lgr5-derived and Sox9-expressing cells needed to trigger Wnt-driven tumor initiation in the intestine.


Sign in / Sign up

Export Citation Format

Share Document